Scarica l'app Stockscreener
0.333
3.80%
0.0122
Dopo l'orario di chiusura:
.32
-0.013
-3.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR
bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat
B of A Securities Downgrades bluebird bio (BLUE) - MSN
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL
Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN
bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA
bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha
bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat
Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com
Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com UK
bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat
JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St
Bluebird: Q3 Earnings Snapshot - Darien Times
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Naviga - GuruFocus.com
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
Bluebird bio Reports Q3 2024 Earnings and Future Outlook - TipRanks
bluebird bio Inc (BLUE) Quarterly 10-Q Report - Quartz
Earnings call: Bluebird bio sees patient growth, aims for 2025 breakeven - Investing.com
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - citybiz
Bluebird bio says it needs cash to operate beyond March 2025 - The Business Journals
Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
BLUE (bluebird bio) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Q3 2024 bluebird bio Inc Earnings Call Transcript - GuruFocus.com
bluebird bio Q3 Revenue Dips to $10.6M, Eyes Break-Even by 2025 Despite Losses | BLUE Stock News - StockTitan
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, - openPR
bluebird bio Q3 2024 Earnings Preview - MSN
Goldman Sachs Group Inc's Strategic Acquisition of Shares in blu - GuruFocus.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Eagle Pharmaceuticals Taps Former Bluebird Bio CFO Krawtschuk to Lead Finance | EGRX Stock News - StockTitan
bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter 2024 Results Call - BioSpace
bluebird bio expands incentive plan amid leadership changes - Investing.com India
Bluebird Bio’s Key Decisions and Shareholder Engagement in 2024 - TipRanks
bluebird bio expands incentive plan amid leadership changes By Investing.com - Investing.com UK
bluebird bio Delays Stock Split Vote, Faces Nasdaq Delisting Risk Amid Capital Needs | BLUE Stock News - StockTitan
What's Going On With Bluebird Bio Stock? - MSN
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - BioSpace
Bluebird bio stock plunges to 52-week low of $0.45 amid downturn - Investing.com Australia
Bluebird Bio to Present Groundbreaking 10-Year Gene Therapy Data at ASH Meeting | BLUE Stock News - StockTitan
BLUE (bluebird bio) Cyclically Adjusted FCF per Share : $-7.77 (As of Jun. 2024) - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Shares in bluebird bio Inc - GuruFocus.com
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
7 children given bluebird's Skysona developed blood cancer: study - MSN
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Receives $4.63 Consensus PT from Analysts - MarketBeat
The Ultimate Biotech Stock to Buy With $50 Right Now - The Motley Fool
bluebird bio (NASDAQ:BLUE) Receives New Coverage from Analysts at StockNews.com - MarketBeat
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):